NCT05743907

Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

A Multicenter, Double-blind, Active-controlled, Randomized, Parallel, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 231 (actual)
• Sponsor: Dong-A ST Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, double-blind, active-controlled, randomized, parallel, phase IV clinical trial to evaluate the efficacy and safety of DA-2811 when added to ongoing metformin monotherapy in patients with type 2 diabetes who have inadequate glycemic control

Conditions

• Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	DA-2811	DA-2811 Group: DA-2811 + Forxiga placebo
DRUG	Forxiga	Forxiga Group: Forxiga + DA-2811 placebo

Timeline

• Start date: 2023-04-25
• Primary completion: 2025-03-10
• Completion: 2025-03-10
• First posted: 2023-02-24
• Last updated: 2025-03-14

Locations

1 site across 1 country: South Korea